Live Price Coverage: Is PONIARD PHARMA (PARD)’s Trend Up

November 28, 2016 - By Nellie Frank

Live Price Coverage: Is PONIARD PHARMA (PARD)’s Trend Up

Penny stock shareholders are becoming inquisitive about PONIARD PHARMA (OTCMKTS:PARD), following the fact that the share price has moved $0.028, reaching the $0.11 price level in a recent trade.

A big benefit of investing in small-cap shares is that there is a prospect to outpace the institutional investors. In addition, mutual funds have limits controlling their power to purchase large lots of any one firm’s outstanding shares.

It’s the latest price, but let’s analyze how the stock has been doing recently. In the past year, PONIARD PHARMA’s stock was -47.00%. According to the short interest report published recently, (PARD) had 100 shorted shares for 0.1 days to cover. The prior short interest was 100 for a $N/A change. The 52-Week High and Low are noted here. -50.00% (High), 83.33%, (Low). The stock had 900 average volume.

Is stock price of PONIARD PHARMA Set to Getaway to Their Potential? Register for Our Newsletter and Know the Inside Scoop!

As seen in stock market, the first point in investing in penny shares is to earn money. A popular trait of penny shares is that they move quickly and are extremely volatile. Penny shares are mainly stocks of small cap firms that can be open to change in industry conditions and stock market sentiments. Though penny shares are generally stated to be dicey, a trader can make massive amount of money in a short period of time, as against bigger, so-named ‘blue chip’ shares and mutual funds, which need a long-term plan.

Needless to state, investing in penny stock is not a right choice for the risk-averse, and only non-essential disposable income or ‘play money’ should be put in penny stocks. In no way are these stocks termed as the conservative investments and traders who play them are willing to take risks with invested capital. Penny stock shareholders must be prepared to put on stake their entire investment. Penny stocks trade fast in directions, recording massive downticks or upticks in few hours.

Receive Breaking Updates by Enrolling to our Newsletter! Hit on the Bar Below and Explore About Stocks that are Set to Make a Run!

Anticipated penny stock investors should learn and gain knowledge of the penny stock market. They must conduct intense research of a firm they might want to invest their money into. Learning can start by enrolling to a penny stock newsletter which offers informative penny stock recommendations. Gathering data as much as you can that is related to the penny stock world is tremendously vital if you want to earn money in trading. It is highly suggested that you enter into the market with a small amount of capital to lessen the risk if you incur a loss.

Disclaimer: The information, views, and opinions expressed in this publication are those of the writers and do not necessarily shows the position or official policy of any company financial professionals, analysts or stakeholders. Examples of assessment performed within this publication are just examples. They should not be used to make financial decisions or stock portfolio as they are based merely on open source and limited information. Assumptions taken within the study are not indicative of the position of any financial professionals or analysts.

More notable recent Poniard Pharmaceuticals, Inc. (OTCMKTS:PARD) news were published by: which released: “NeoRx Corporation (Poniard Pharmaceuticals) Reports First Quarter Financial …” on May 15, 2006, also with their article: “Verastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718” published on February 25, 2014, published: “Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small …” on June 05, 2010. More interesting news about Poniard Pharmaceuticals, Inc. (OTCMKTS:PARD) were released by: and their article: “Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces …” published on November 21, 2011 as well as‘s news article titled: “KaloBios Appoints Ronald A. Martell Executive Chairman” with publication date: May 28, 2015.

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $135,234. The Firm focuses on the development and commercialization of oncology products to impact the lives of people with cancer. It currently has negative earnings. It develops picoplatin, a platinum chemotherapeutic agent that is in clinical development for multiple cancer indications, treatment combinations and by two routes of administration.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News